Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Jul 11, 2019
Emerging Company Profile
Twentyeight-Seven’s bet on RNA-binding proteins
Twentyeight-Seven is capitalizing on the emerging biology of RNA-binding proteins by targeting their interactions with non-coding RNAs
BioCentury | Mar 29, 2019
Targets & Mechanisms
Next-wave targets at AACR 2019 start filling the blanks in the tumor microenvironment
A look at new and emerging targets at AACR 2019 and their mechanisms
BioCentury | Jun 23, 2016
Translation in Brief
Musashi's dual duel
Musashi homolog 2 (MSI2) promotes cancer metastasis and therapy resistance
Items per page:
1 - 5 of 5